3Zhou D,Andersson T B,Grimm S W.In vitro evaluation of potential drug-drug interactions with ticagrelor:cytochrome P450 reaction phenotyping,inhibition,induction,and differential kinetics[J].Drug Metabolism and Disposition,2011,39(4):703-710.
4Storey R F.Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors[J].Thrombosis and haemostasis,2011,105(1):S75.
6Wallentin L,Becker R C,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].New England Journal of Medicine,2009,361(11):1045-1057.
7Payal K,Lars W,Eric R,et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study[J].Coronary Heart disease,2013,127:673-680.
8Alexopoulos D,Galati A,Xanthopoulou I,et al.Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention A Pharmacodynamic Study[J].Journal of the American College of Cardiology,2012,60(3):193-199.
9Cannon C P,Harrington R A,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):a randomised double-blind study[J].The Lancet,2010,375(9711):283-293.
10James SK,Roe MT,Cannon CP,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management:substudy from prospective randomised PLATelet inhibition and patient Outcomes(PLATO)trial[J].British Medical Journal,2011,342:d3527.
2Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.- The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2011,32(23) : 2999-3054.
3Arora RR, Rai F. Antiplatelet intervention in acute coronary syndrome[J]. Am J Ther, 2009, 16 (5) : e29-e40.
4Wiviott SD, Braunwald E, McCabe CH, et al. Pra- sugrel versus clopidogrel in patients with acute cor- onary syndromes[J]. N Engl J Med, 2007,357 (20) : 2001-2015.
5Husted S, van Giezen JJ. Ticagrelor: the first re- versibly binding oral P2Y12 receptor antagonist [J]. Cardiovasc Ther,2009,27(4) : 259-274.
6Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11) : 1045- 1057.
7Brilinta (ticagrelor) Tablets: A P2Y(12) platelet inhibitor indicated to reduce the rate of thromboticcardiovascular events in patients with acute coro- nary syndrome (ACS)[J]. P T, 2012,37(4 section 2) : 4-18.
8Teng R, Butler K. Pharmacokinetics, pharmacody- namics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y (12) receptor antagonist, in healthy subjects[J]. Eur J Clin Pharmacol,2010,66(5) : 487-496.
9Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ti- cagrelor in healthy subjects[J] Drug Metab Dispos, 2010,38(9) : 1514-1521.
10Storey RF, Husted S, Harrington RA, et al. Inhi- bition of platelet aggregation by AZD6140, a re- versible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 2007,50 (19) : 1852-1856.
